ProPhase Labs Statistics
Total Valuation
ProPhase Labs has a market cap or net worth of $14.04 million. The enterprise value is $37.93 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ProPhase Labs has 41.88 million shares outstanding. The number of shares has increased by 18.92% in one year.
| Current Share Class | 41.88M |
| Shares Outstanding | 41.88M |
| Shares Change (YoY) | +18.92% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 7.96% |
| Owned by Institutions (%) | 6.06% |
| Float | 38.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.01 |
| Forward PS | 0.17 |
| PB Ratio | 1.36 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.95, with a Debt / Equity ratio of 3.34.
| Current Ratio | 0.95 |
| Quick Ratio | 0.65 |
| Debt / Equity | 3.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.53 |
Financial Efficiency
Return on equity (ROE) is -174.58% and return on invested capital (ROIC) is -48.40%.
| Return on Equity (ROE) | -174.58% |
| Return on Assets (ROA) | -31.13% |
| Return on Invested Capital (ROIC) | -48.40% |
| Return on Capital Employed (ROCE) | -124.34% |
| Revenue Per Employee | $70,521 |
| Profits Per Employee | -$555,875 |
| Employee Count | 96 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 4.03 |
Taxes
In the past 12 months, ProPhase Labs has paid $7.20 million in taxes.
| Income Tax | 7.20M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.50% in the last 52 weeks. The beta is -0.55, so ProPhase Labs's price volatility has been lower than the market average.
| Beta (5Y) | -0.55 |
| 52-Week Price Change | -93.50% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 1.42 |
| Relative Strength Index (RSI) | 48.74 |
| Average Volume (20 Days) | 2,475,417 |
Short Selling Information
The latest short interest is 1.19 million, so 2.84% of the outstanding shares have been sold short.
| Short Interest | 1.19M |
| Short Previous Month | 793,412 |
| Short % of Shares Out | 2.84% |
| Short % of Float | 3.08% |
| Short Ratio (days to cover) | 0.62 |
Income Statement
In the last 12 months, ProPhase Labs had revenue of $6.77 million and -$53.36 million in losses. Loss per share was -$2.61.
| Revenue | 6.77M |
| Gross Profit | -150,000 |
| Operating Income | -38.63M |
| Pretax Income | -32.20M |
| Net Income | -53.36M |
| EBITDA | -32.44M |
| EBIT | -38.63M |
| Loss Per Share | -$2.61 |
Full Income StatementBalance Sheet
The company has $678,000 in cash and $24.57 million in debt, giving a net cash position of -$23.90 million or -$0.57 per share.
| Cash & Cash Equivalents | 678,000 |
| Total Debt | 24.57M |
| Net Cash | -23.90M |
| Net Cash Per Share | -$0.57 |
| Equity (Book Value) | 7.35M |
| Book Value Per Share | 0.25 |
| Working Capital | -1.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.54 million and capital expenditures -$906,000, giving a free cash flow of -$18.44 million.
| Operating Cash Flow | -17.54M |
| Capital Expenditures | -906,000 |
| Free Cash Flow | -18.44M |
| FCF Per Share | -$0.44 |
Full Cash Flow StatementMargins
| Gross Margin | -2.22% |
| Operating Margin | -570.59% |
| Pretax Margin | -625.26% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |